Index
971
aztreonam, 91, 104–105, 122, 123
bacteria and, 91–93
resistance, 94
carbapenems, 90, 97–99
adverse effects, 98
care considerations, 99
contraindications and cautions, 98
drug–drug interactions, 98
pharmacokinetics, 97–98
therapeutic actions and indications,
97
cellular actions, sites, 92
cephalosporins, 90, 99–103
adverse effects, 101–102
calculations, 101
care considerations, 102–103
contraindications and cautions, 101
drug–drug interactions, 102
pharmacokinetics, 101
therapeutic actions and indications,
101
children, 93
fluoroquinolones, 90, 106–108
adverse effects, 106–107
care considerations, 107–108
contraindications and cautions, 106
drug–drug interactions, 107
pharmacokinetics, 106
therapeutic actions and indications,
106
lincosamides, 104, 105–106, 122
adverse effects, 104
care considerations, 105–106
contraindications and cautions, 104
pharmacokinetics, 104
therapeutic actions and indications,
104
macrolides, 91, 103–104, 105–106, 122
adverse effects, 104
care considerations, 105–106
contraindications and cautions,
103–104
drug–drug interactions, 104
drug–food interactions, 104
pharmacokinetics, 103
therapeutic actions and indications,
103
monobactum antibiotic, 104–106, 122
adverse effects, 105
care considerations, 105–106
contraindications and cautions, 105
pharmacokinetics, 105
therapeutic actions and indications,
104
new classes and adjuncts, 121
daptomycin, 121
linezolid (Zyvox), 121
tigecycline, 114, 121
older adults, 93
oral contraceptives and, 115–117
penicillins and penicillinase-resistant
antibiotics, 90, 108–111
adverse effects, 110
care considerations, 110–111
contraindications and cautions, 110
drug–drug interactions, 110
education regarding, 111
pharmacokinetics, 109–110
therapeutic actions and indications,
108–109
risks and dangers of antibiotic abuse, 94
sulfonamides, 91, 112–114
adverse effects, 113
care considerations, 113–114
contraindications and cautions, 112
drug–drug interactions, 113
pharmacokinetics, 112
therapeutic actions and indications,
112
tetracyclines, 91, 114–115, 117–118
adverse effects, 115
care considerations, 117–118
contraindications and cautions,
114–115
drug–drug interactions, 115
drug–food interactions, 115
pharmacokinetics, 114
therapeutic actions and indications,
114
Antibodies, 228, 233–234
Anticholinergic agents, 372, 379–381,
501–509, 864, 867, 873–875
adults, 502
adverse effects, 380, 505, 874
care considerations, 381, 507, 874–875
children, 502
contraindications and cautions, 380,
503–505, 874
drug–drug interactions, 380–381,
505–506, 874
heart disease, 508–509
older adults, 502
pharmacokinetics, 380, 503, 873
therapeutic actions and indications,
379–380, 502–503, 873
Anticoagulants, 750, 751, 756–757,
759–764
adjunctive therapy, 751, 757–758, 766
adverse effects, 762
care considerations, 763–764
contraindications and cautions, 762
drug–drug interactions, 762–763
oral therapy, 760–762
pharmacokinetics, 762
therapeutic actions and indications, 760
Antidepressant agents, 316–332
adults, 318
child suicide and, 328
children, 318
depression, 317
biogenic amine theory, 317
discontinuation syndrome, 321
miscellaneous drugs, 330–331
agomelatine, 330, 331
bupropion, 330, 331
desvenlafaxine, 330–331
mianserin, 331
mirtazapine, 331
moclobemide, 331
reboxetine, 331
selegiline, 331
venlafaxine, 331
monoamine oxidase (MAO) inhibitors,
316, 323–325
adverse effects, 323–324
care considerations, 325
contraindications and cautions, 323
drug–drug interactions, 324
drug–food interactions, 324
pharmacokinetics, 323
therapeutic actions and indications,
323
older adults, 318
pregnancy, during, 318
safe medication administration, 327
selective serotonin reuptake inhibitors
(SSRIs), 316, 325–330
adverse effects, 327–328
care considerations, 328–329
contraindications and cautions,
326–327
critical thinking scenario, 329–330
drug–drug interactions, 328
pharmacokinetics, 326
therapeutic actions and indications,
326
tricyclic antidepressants (TCA), 316,
317–322
adverse effects, 321
care considerations, 322
contraindications and cautions, 320
drug–drug interactions, 321–322
pharmacokinetics, 320
therapeutic actions and indications,
317–318, 320
Antidiarrhoeals, 916, 923–926
adverse effects, 924
care considerations, 926
combination products, 923
contraindications and cautions, 924
drug–drug interactions, 924
pharmacokinetics, 923
therapeutic actions and indications, 923
Antidiuretic hormone (ADH), 794, 798
Antiemetic agents, 929–937
5-HT
3
receptor blockers, 929, 931–932,
934–935
adults, 931
care considerations, 936–937
children, 931
dopamine D2 receptor antagonists, 934
older adults, 931
phenothiazines, 929, 930–932, 934
substance P/neurokinin 1 receptor
antagonists, 929, 932, 935–936
Antiepileptics, 352, 353, 361–363
critical thinking scenario, 363–365
Antifungal agents, 150–161
adults, 151
children, 151
older adults, 151
pregnancy and breastfeeding, 151
sites of action, 153
systemic, 150, 151–157
azole antifungals, 150, 151–154
care considerations, 156–157
echinocandin antifungals, 150, 152,
154–155
